Clinical Management and Toxicity Considerations of ADCs

This webinar will explore:

    • Advanced toxicity prediction and proactive management strategies
    • Identification of adverse events and management best practices
    • Practical approaches to ADC therapy optimization
    • Patient education for optimizing quality of life while on treatment
    • The APP's role in the management of patients receiving ADCs


This event was sponsored by Gilead, AstraZeneca, Astellas and Pfizer

Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP

Rutgers Cancer Institute

Srigowri Kota, MSN, BA, APN, AGNP-C, AOCNP, is a nurse practitioner in the GU Medical Oncology Group at Rutgers Cancer Institute. In her role, she manages patients on chemotherapy, oral oncolytics, bio/immunotherapy, antibody-drug conjugates (ADCs), targeted therapies, and clinical trials, calling on her in-depth oncology-specific knowledge base for clinical decision capability. Ms. Kota initially joined Rutgers Cancer Institute as a nurse clinician in adult infusion and then transferred to the Stacy Goldstein Breast Cancer Center. She moved into her current role after graduating from the nurse practitioner program at Drexel University. Her nursing experience includes medical oncology in community, inpatient, and outpatient settings. Ms. Kota has been an author on several publications and is frequently engaged as an expert speaker in the identification and management of toxicities and adverse events from ADC therapy in oncology.

Key:

Complete
Failed
Available
Locked
Clinical Management and Toxicity Considerations of ADCs
Open to view video.  |  55 minutes
Open to view video.  |  55 minutes Explore strategies for predicting and managing ADC-related toxicities, optimizing therapy, educating patients, and defining the APP’s role in care.
You must register to access.
Survey
6 Questions
6 Questions
You must register to access.